JRP Bio completes human study of SH003 on immune function
Randomized, double-blind, placebo-controlled design — registration as a functional ingredient under review
JRP Bio (Jaein R&P Co., Ltd.) announced that it has completed a human study evaluating the effect of SH003 on immune function. The study used a randomized, double-blind, placebo-controlled design, and its protocol was published in BMC Complementary Medicine and Therapies (2025).
SH003 is an oral botanical drug candidate derived from a Korean medicine formula whose immune-enhancing effects have been studied alongside its anticancer research. Based on the results, the company is reviewing registration with the MFDS as an individually recognized functional ingredient for immunity.
JRP Bio designs a single asset for several targets — prescription drug, OTC drug, functional ingredient and overseas registration — and generates evidence in the format each target's review requires.
About JRP Bio
JRP Bio (Jaein R&P Co., Ltd.) standardizes Korean medicine formulas and natural products, builds the evidence behind them, and secures approval to turn them into products people actually use. JRP stands for “Journey from Research to People.” The company received Korea's first IND for an oral botanical anticancer candidate, SH003, and holds 14 granted Korean patents and 42 SCI(E) publications.
Media contact
- Email bs@jrpbio.com
- Phone +82-2-6925-5568